References: -
1. Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF, et al. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Med. 2020 Jul;9(13):4512–26.
2. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 9;8(2):15.
3. Al-Mashdali AF, Kashgary WR, Yassin MA. Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report. Medicine (Baltimore). 2021 Nov 5;100(44):e27722.
4. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018 Jan 10;8(1):3.
5. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010 Sep;40(9):828–34.
6. Lelonek E, Matusiak Ł, Wróbel T, Szepietowski JC. Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics. Acta Derm Venereol. 2018 Apr 27;98(5):496–500.
7. Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol. 2008 Jun;83(6):451–3.
8. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006 Aug 1;107(3):451–8.
9. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15;120(4):513–20.
10. Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017 Jan;176(1):76–85.
11. Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018 Sep;97(9):1591–600.
12. Yassin MA, Al-Dewik NI, ElAyoubi H, Cassinat B. Efficacy and safety of pegelated interferon alpha2a once monthly compared to once weekly dose in patients with essential thrombocythemia. Blood. 2013 Nov 15;122(21):4054.
13. Taher A, Yassin MA, Xiao Z, Hou HA, Tuglular T, Mathews V, Rippin G, Sadek I, Siddiqui A, Wong RS. Impact of myeloproliferative neoplasms (MPNs) on health-related quality of life (HRQOL) and medical resource utilization: results from the MERGE registry. Blood. 2018 Nov 29;132:4311.
14. Yassin MA, Nehmeh SA, Nashwan AJ, Kohla SA, Mohamed SF, Ismail OM, Al Sabbagh A, Ibrahim F, Soliman DS, Szabados L, Fayad H. A study of 18F-FLT positron emission tomography/computed tomography imaging in cases of prefibrotic/early primary myelofibrosis and essential thrombocythemia. Medicine. 2020 Nov 6;99(45).
15. Sasi S, Mohamed M, Chitrambika P, Yassin MA. Myasthenia Gravis and Myeloproliferative Neoplasms–Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review. Acta Bio Medica: Atenei Parmensis. 2022;92(6).
16. Ali EA, Abu-Tineh M, Hailan Y, Al-maharmeh QA, Maat ZO, Babiker AM, Ali B, Ismail AS, Yassin MA. The Outcome of Fatherhood in Patients with Philadelphia Negative Myeloproliferative Neoplasms, a Single Institution Experience “. Blood. 2021 Nov 23;138:4625.
16. Ali EA, Abu-Tineh M, Hailan Y, Al-maharmeh QA, Maat ZO, Babiker AM, Ali B, Ismail AS, Yassin MA. The Outcome of Fatherhood in Patients with Philadelphia Negative Myeloproliferative Neoplasms, a Single Institution Experience “. Blood. 2021 Nov 23;138:4625.